Literature DB >> 594644

Increased transcapillary escape rate of albumin in patients with cirrhosis of the liver.

H H Parving, L Ranek, N A Lassen.   

Abstract

The transcapillary escape rate of albumin (TERalb), i.e. the fraction of intravascular mass of albumin that passes to the extravascular space per unit time, was determined from the disappearance of intravenously injected 125I-labelled human serum albumin during the first 60 min after injection in nine patients with cirrhosis of the liver. Six of the patients had ascites. The wedged hepatic venous pressure or splenic pulp pressure ranged from 20 to 30 mmHg, mean 26 mmHg. Plasma albumin concentration was low, but plasma volume was slightly enlarged, and thus the intravascular mass of albumin was only moderately reduced. The transcapillary escape rate of albumin was significantly elevated in all the cirrhotics, mean 10.2%/h, range 8.8 to 12.3%/h, in comparison to values for twenty-eight normal subjects 5.4%/h, range 3.5-7.2%/h. Our results can best be explained by increased filtration out of the vessels in the portal system, due to the increased portal venous pressure. The increased TERalb probably contributes to the formation of oedema and ascitic fluid.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 594644     DOI: 10.3109/00365517709100658

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  8 in total

1.  5 Human Albumin.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

2.  Intravascular volume in cirrhosis. Reassessment using improved methodology.

Authors:  W G Rector; F Ibarra
Journal:  Dig Dis Sci       Date:  1988-04       Impact factor: 3.199

3.  Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability.

Authors:  Paul R V Malik; Abdullah Hamadeh; Colin Phipps; Andrea N Edginton
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-03-04       Impact factor: 2.745

4.  Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites.

Authors:  P A McCormick; P Mistry; G Kaye; A K Burroughs; N McIntyre
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

5.  Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised.

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-03       Impact factor: 3.747

Review 6.  Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

Authors:  Paul Malik; Colin Phipps; Andrea Edginton; Jonathan Blay
Journal:  Pharm Res       Date:  2017-09-18       Impact factor: 4.200

Review 7.  [Guidelines on therapy with blood components and plasma derivatives: human albumin. Recommendations of the scientific advisory board of the Medical Council].

Authors:  J Boldt
Journal:  Anaesthesist       Date:  2010-06       Impact factor: 1.041

Review 8.  Lymphatic dysfunction in advanced cirrhosis: Contextual perspective and clinical implications.

Authors:  Ramesh Kumar; Utpal Anand; Rajeev Nayan Priyadarshi
Journal:  World J Hepatol       Date:  2021-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.